As we near the end of the year, we bring you this years’ top five research breakthroughs and announcements coming from JDRF Australia-funded type 1 diabetes (T1D) research. And what a year it was! With support from JDRF Australia, researchers made the groundbreaking discoveries around supressing T1D and being able to regenerate insulin-producing beta cells […]
In the fight against T1D, funding research alone is not enough. For breakthroughs to reach people living with T1D, concerted and strategic effort is needed so that research discoveries are moved to the next stages of development. This is why JDRF is committed to not only funding research projects but also driving them forward through […]
It is with heavy hearts that JDRF Australia and Breakthrough T1D farewell Professor Helen Thomas following her recent passing. Professor Thomas was a great in the world of type 1 diabetes (T1D) research and collaborator on many of T1D research projects across Australia. She was a recognised international leader who made significant advancements in the […]
JDRF Australia is proud to announce that the next round of Career Support and Travel Grants is now open. JDRF Australia aims to support the next generation of type 1 diabetes (T1D) researchers by helping them with skills development or facilitating them to present and attend scientific conferences. This enables them to gain new skills, […]
JDRF Australia is committed to a vision of a world without type 1 diabetes (T1D) through funding the best science. But research can only be done by researchers. This is why we have a strong focus on not only funding established researchers but also investing in the development of those earlier on in their career […]
A new trial called the ASITI-201 Study is looking for participants based in Queensland to test a potential new therapy for type 1 diabetes (T1D). The therapy is designed to stop the immune system attack that characterises the condition. T1D is an autoimmune condition where the immune system mistakenly attacks the insulin-producing beta cells of […]
New research has found that preschoolers who are in the early, pre-symptomatic stages of type 1 diabetes (T1D) have changes in blood sugar levels well before symptoms appear. We used to think that people developed T1D when they first showed the ‘4T’ symptoms: thirst, tiredness, toilet (increased urination) and thin (weight loss). This is when […]
A new clinical trial investigating the use of semaglutide for type 1 diabetes (T1D) has launched in Sydney and is actively recruiting. The trial, called REducing Cardiometabolic Risk with SEmaglutide in Type 1 diabetes (The RESET1 study) is looking for adults to test whether semaglutide, a medication currently used to treat type 2 diabetes, can […]
Australian researcher Professor Christoph Hagemeyer from Monash University and colleagues have received over $750,000 to take their innovative new insulin formulation to the next stage of research. In people with type 1 diabetes (T1D), the immune system incorrectly attacks the cells of the pancreas that normally produce insulin, a hormone essential to regulate blood sugar […]
Screening and monitoring will bring forward diagnoses and make early detection of the condition a reality Type 1 diabetes (T1D) diagnoses could soon be transformed with newly released guidance outlining how to detect and monitor early-stage T1D, before the point of symptom onset. The chronic autoimmune condition is traditionally diagnosed when elevated blood glucose levels […]
A new study has added to the evidence that people develop type 1 diabetes (T1D) at different rates, and that a blood test can predict when this may occur We used to think that people only developed T1D when they showed the ‘4T symptoms’: thirst, tiredness, toilet (increased urination) and thin (weigh loss). And while […]
Three Early to Mid-Career researchers (EMCRs) awarded the Tim Welborn EMCR Fellowship JDRF Australia is happy to announce that three promising researchers will be supported under the Tim Welborn Early-to-Mid Career Research (EMCR) Fellowship for basic research. This award funds the next generation of type 1 diabetes (T1D) researchers to ensure their career development is […]
JDRF Australia and JDRF International have announced over $3m AUD in funding for researchers aiming to improve health outcomes for the type 1 diabetes (T1D) community by making precision medicine possible. Precision medicine has delivered great benefits in other disease areas, such as cancer, and involves treatment that is tailored to a person’s genes, environment, […]
We are proud to announce that Dr Kirstine Bell from the Charles Perkins Centre at The University of Sydney has been awarded the 2023 JDRF Dr Robert Goldstein Award for her notable contributions to type 1 diabetes (T1D) research. This is an internationally competitive award given to early career researchers who show great promise in […]
JDRF is proud to announce new funding of $200,000 (USD) to Dr Irina Buckle from Mater Research and The University of Queensland, to undertake a project which aims to understand what may be driving type 1 diabetes. Type 1 Diabetes (T1D) is a condition where certain types of immune cells, known as T cells, incorrectly […]
A research group from Norway has found that adding small amounts of glucagon to insulin speeds up its action. For people with type 1 diabetes (T1D) this would mean a faster acting insulin than what is on the market, and in turn, improved quality of life. The need for fast insulin T1D is an autoimmune […]
JDRF is delighted to announce that three Australian Early to Mid-Career Researchers (EMCRs) are being supported with over $2.2 million to continue their groundbreaking type 1 diabetes (T1D) research. JDRF is committed to nurturing the growth and impact of leading independent researchers who are instrumental in translating scientific discoveries to clinical applications. Dr Aveni Haynes […]
JDRF, the leading global type 1 diabetes (T1D) research and advocacy organisation, joins healthcare and humanitarian non-profits throughout the world in calling for a medical corridor to allow immediate access to lifesaving supplies and medicines, like insulin, needed by all people living with T1D in the Middle East conflict zone. At all times, including times […]